Thomas A. Mccourt - 11 Jun 2026 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Reporting relationship: Director
Issuer ticker: PLRX
Reported as of: 11 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 17:01:20 UTC
Prior SEC filing: 12 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Woo, attorney-in-fact

Key filing fact

Thomas A. Mccourt filed Form 4 for PLIANT THERAPEUTICS, INC. (PLRX) on 12 Jun 2026.

Key facts

This page summarizes Thomas A. Mccourt's Form 4 filing for PLIANT THERAPEUTICS, INC. (PLRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2026, 17:01.

Change

Previous filing in this sequence was filed on 12 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001478448 Primary reporting owner

MCCOURT Thomas A

Relationship: Director
Address: C/O PLIANT THERAPEUTICS, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO
Signature: /s/ Jennifer Woo, attorney-in-fact
Signature date: 12 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PLRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +70,000
Change %
Price: $0.000000^*
Shares after: 70,000
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 70,000
Exercise price: $1.14
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.